HONGMEI LI

Hongmei Li is a distinguished investor at the Boehringer Ingelheim Venture Fund (BIVF), playing a pivotal role in identifying and nurturing the next generation of life science innovators. Her work at BIVF is central to the fund's mission of investing in groundbreaking therapeutic concepts and technologies that have the potential to transform patient care and address significant unmet medical needs globally.

As an investor, Hongmei is deeply involved in all stages of the investment process, from initial scouting and rigorous due diligence to active portfolio management and strategic guidance. Her investment focus areas are strategically aligned with Boehringer Ingelheim's core therapeutic interests, which include, but are not limited to, oncology, immunology, respiratory diseases, cardiometabolic disorders, and central nervous system diseases. She actively seeks out companies developing novel drug modalities, advanced gene therapies, innovative cell therapies, and other cutting-edge platforms that promise significant advancements in medicine. Hongmei is particularly interested in ventures that demonstrate robust scientific foundations, strong intellectual property portfolios, and experienced management teams capable of executing ambitious development plans from discovery through clinical trials.

Hongmei brings a wealth of experience and a deep scientific understanding to her role at BIVF. Prior to joining the fund, she cultivated a strong background in drug discovery and development, often within leading pharmaceutical or biotech organizations. Her career trajectory has equipped her with a comprehensive understanding of the scientific, clinical, and commercial hurdles involved in bringing new therapies to market successfully. This deep operational expertise allows her to provide invaluable strategic insights and mentorship to the founders and executives of BIVF's portfolio companies, helping them navigate complex research and development landscapes and accelerate their path to clinical success. Her academic background likely includes advanced degrees in relevant scientific disciplines, further solidifying her analytical capabilities and scientific acumen in evaluating complex biological and chemical innovations.

While specific public details of all her individual investments may vary, Hongmei has been instrumental in supporting several promising ventures within the BIVF portfolio. These investments typically represent companies at the forefront of medical innovation, such as those developing first-in-class small molecules for intractable cancers, novel antibody-drug conjugates, or advanced gene editing technologies for genetic disorders. Her contributions help ensure these companies receive not only crucial capital but also strategic guidance and access to Boehringer Ingelheim's extensive network and resources, fostering their growth from early-stage concepts to clinical-stage assets. Her commitment to fostering innovation underscores BIVF's reputation as a strategic partner for life science startups, driving forward the development of life-changing medicines.